Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 13
Submit an article Journal homepage
3,017
Views
10
CrossRef citations to date
0
Altmetric
Original Articles

Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation–positive acute myeloid leukemia: the RADIUS-X expanded access program

Gail J. Roboza Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USACorrespondence[email protected]
View further author information
,
Stephen A. Stricklandb Vanderbilt-Ingram Cancer Center, Nashville, TN, USAORCID Iconhttps://orcid.org/0000-0002-6861-2041View further author information
ORCID Icon,
Mark R. Litzowc Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-9816-6302View further author information
ORCID Icon,
Andrew Dalovisiod Ochsner Medical Center, New Orleans, LA, USAView further author information
,
Alexander E. Perle University of Pennsylvania, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0002-1463-2231View further author information
ORCID Icon,
Gaetano Bonifaciof Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Kelly Hainesf Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Alysha Barberaf Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Das Purkayasthaf Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
&
Kendra Sweetg Moffitt Cancer Center, Tampa, FL, USAView further author information
 show all
Pages 3146-3153 | Received 20 Jan 2020, Accepted 27 Jul 2020, Published online: 19 Aug 2020

References

  • Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
  • Gregory TK, Wald D, Chen Y, et al. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009;2:23
  • Pratcorona M, Brunet S, Nomdedéu J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121(14):2734–2738.
  • Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752–1759.
  • Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650–665.
  • Murphy K, Weaver C, Mowat A, et al. Janeway’s immunobiology. Quart Rev Biol. 2018;93(1):59–59.
  • Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089.
  • Nagel G, Weber D, Fromm E, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96(12):1993–2003.
  • Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464.
  • Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114(12):2386–2392.
  • Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2018;59(10):2273–2286.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335.
  • Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776–2784.
  • Koszarska M, Meggyesi N, Bors A, et al. Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort. Leuk Lymphoma. 2014;55(7):1510–1517.
  • Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood. 2008;111(5):2527–2537.
  • Boddu P, Kantarjian H, Borthakur G, et al. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017;1(19):1546–1550.
  • Santos FP, Jones D, Qiao W, et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011;117(10):2145–2155.
  • Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol. 2001;19(5):1485–1492.
  • Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1(5):433–443.
  • Rydapt [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2020.
  • Rydapt [summary of product characteristics]. Basel, Switzerland: Novartis Pharmaceuticals AG; 2018.
  • National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Acute Myeloid Leukemia. V1. 2015.
  • Common terminology criteria for adverse events v4.03. Bethesda (MD): National Cancer Institute; 2010.
  • Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840–851.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.